Compare Lithium Americas Corp (LAC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Lithium Americas Corp trades at $3.26 (market cap $1.18B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 112.5× Lithium Americas Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| LAC | VRTX | |
|---|---|---|
Market Cap | $1.18B | $132.79B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $529.65 |
52-Week Low | $2.71 | $376.62 |
Enterprise Value | $1.30B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $3.23, up 6.95% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $122.09 million for 2025 and continues to burn cash from operations. Recent news highlights $175 million financing for Thacker Pass construction, providing balance sheet support amid ongoing capital expenditures exceeding $900 million annually.
While analyst consensus leans positive with no sell ratings, significant execution risks persist as LAC navigates peak construction phase. The stock faces headwinds from negative ROE (-11.35%) and cash burn, though strategic positioning in lithium development offers long-term potential if project timelines and funding are successfully managed.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
